XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea (CSD) in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Request a XERMELO representative

Enter your information below to have your representative send you information about XERMELO.

Fields marked with an asterisk (*) are required.

Enter your NPI number.
Enter a valid NPI number.

Need your NPI number? Look it up here.

Your NPI number must be in your name and not shared across your facility or in the name of any other person.

 
Enter your first name.
Enter your last name.
Your last name does not match the last name for the NPI number provided.
Enter your office address.
Enter your city.
Select your state.
Enter your ZIP code.
Enter a valid ZIP code.
Enter your email address.
Enter a valid email address.

By clicking Submit, you agree to receive information from TerSera Therapeutics and its partners.

By submitting this form, I verify that I am a healthcare professional and agree to the privacy policy below.

We respect your privacy.

By submitting this form, I understand that the information I have provided will be used by TerSera and its contracted third parties to contact me by mail, email, and/or phone with helpful information on TerSera treatments and indicated conditions. TerSera will not sell or transfer my name or contact information to any third party for their marketing use.

I understand that I may revoke this authorization at any time by sending written notice of revocation to TerSera Therapeutics at 520 Lake Cook Road, Suite 500, Deerfield, IL, 60015, except to the extent that action already has been taken in reliance on this authorization. To learn more, read our Privacy Policy.

Important Safety Information and Indication

  • Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Adverse Reactions: In a clinical trial of patients with carcinoid syndrome diarrhea and 4-12 bowel movements per day, the most common adverse reactions (≥5%) include nausea, headache, increased gamma-glutamyl transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia. In a second clinical trial of patients with carcinoid syndrome diarrhea and less than 4 bowel movements per day, additional adverse reactions of abdominal pain and constipation were reported in ≥5% of patients.
  • Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 and CYP2B6 substrates, as XERMELO may decrease their systemic exposure. If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO.
  • Use in Special Populations: XERMELO is not recommended in patients with moderate and severe hepatic impairment.

Indication

XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Please see Full Prescribing Information.

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch. You may also contact TerSera Therapeutics at 1-844-334-4035 or medicalinformation@tersera.com.

 

Important Safety Information and Indication

  • Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Contraindications: XERMELO is contraindicated in patients with a history of a hypersensitivity reaction to telotristat. Reactions have included angioedema, rash and pruritis.
  • Warnings and Precautions: XERMELO may cause constipation, which can be serious. Serious complications of constipation have been reported during clinical trials and post marketing with individual reports of intestinal perforation, obstruction, and fecaloma. Monitor for signs and symptoms of constipation and/or severe, persistent, or worsening abdominal pain in patients taking XERMELO. Discontinue XERMELO if severe constipation or severe, persistent, or worsening abdominal pain develops.
  • Adverse Reactions: In a clinical trial of patients with carcinoid syndrome diarrhea and 4-12 bowel movements per day, the most common adverse reactions (≥5%) include nausea, headache, increased gamma-glutamyl transferase, depression, flatulence, decreased appetite, peripheral edema, and pyrexia. In a second clinical trial of patients with carcinoid syndrome diarrhea and less than 4 bowel movements per day, additional adverse reactions of abdominal pain and constipation were reported in ≥5% of patients.
  • Drug Interactions: If necessary, consider increasing the dose of concomitant CYP3A4 and CYP2B6 substrates, as XERMELO may decrease their systemic exposure. If combination treatment with XERMELO and short-acting octreotide is needed, administer short-acting octreotide at least 30 minutes after administering XERMELO.
  • Use in Special Populations: XERMELO is not recommended in patients with moderate and severe hepatic impairment.

Indication

XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Please see Full Prescribing Information.

To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.FDA.gov/medwatch. You may also contact TerSera Therapeutics at 1-844-334-4035 or medicalinformation@tersera.com.

Attention

If you click “Continue” below, you will leave the current site and be taken to a site maintained by a third party who is solely responsible for its content. TerSera provides this link as a service to website visitors. TerSera is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Continue

NPI LOOKUP

To find your NPI number, please fill out the information below.

Fields marked with an asterisk (*) are required.

Enter your first name.
Enter your last name.
Select your state.

Search results

Select the entry with your name and address information.  

Name NPI number State ZIP Code  

No results found

Refine your search and try again.